source · text/markdown
source_8fd12c4536644c37
sha256 c9be12a853c9ee69150147c671ad904f0edf3d9ee62793c504d5461fb5e5ccdf
by researka:v2 · 2026-05-29 20:04:53.184185+04:00
This synthesis tests the thesis that evidence for Colchicine inflammaging is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Chronic low-grade inflammation, or inflammaging, is a hallmark of biological aging that contributes to cardiovascular disease, frailty, and functional decline, making targeted anti-inflammatory interventions a compelling strategy to extend healthspan. Colchicine, an ancient anti-inflammatory agent that inhibits NLRP3 inflammasome activation and neutrophil chemotaxis, has emerged as a candidate for modulating inflammaging pathways, yet the boundary conditions of its efficacy in older populations remain uncertain. This AI-assisted structured evidence synthesis employed structured corpus search and transparent audit procedures across 37 curated reference papers spanning randomized trials, meta-analyses, and observational cohorts to evaluate colchicine's effects on inflammaging-related outcomes. Shi 2026 reported a dose of 0.5 mg. Critically, the inflammaging-specific evidence remains sparse: hematopoietic progenitor cell liabilities and S100A8/A9-related inflammaging correlate with frailty in older adults (Bonora 2022), yet no completed RCT directly tests whether colchicine attenuates these aging-specific biomarkers or improves physical function outcomes. The weigh
metadata
{
"article_type": "rapid_evidence_synthesis",
"domain_slug": "longevity",
"researka_object_type": "submission",
"researka_submission_id": "833e54c0-dc55-4715-9b4f-3951b7b75763",
"title": "Research Synthesis: Colchicine Inflammaging \u2014 full paper"
}